Correlation Between Boston Scientific and Immunome

Can any of the company-specific risk be diversified away by investing in both Boston Scientific and Immunome at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Boston Scientific and Immunome into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Boston Scientific Corp and Immunome, you can compare the effects of market volatilities on Boston Scientific and Immunome and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Boston Scientific with a short position of Immunome. Check out your portfolio center. Please also check ongoing floating volatility patterns of Boston Scientific and Immunome.

Diversification Opportunities for Boston Scientific and Immunome

-0.25

Correlation Coefficient

Boston Scientific  Immunome

Very good diversification

The 3 months correlation between Boston and Immunome is -0.25. Overlapping area represents the amount of risk that can be diversified away by holding Boston Scientific Corp and Immunome in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Immunome and Boston Scientific is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Boston Scientific Corp are associated (or correlated) with Immunome. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Immunome has no effect on the direction of Boston Scientific i.e., Boston Scientific and Immunome go up and down completely randomly.

Pair Corralation between Boston Scientific and Immunome

Considering the 90-day investment horizon Boston Scientific Corp is expected to generate 0.31 times more return on investment than Immunome. However, Boston Scientific Corp is 3.18 times less risky than Immunome. It trades about 0.14 of its potential returns per unit of risk. Immunome is currently generating about -0.11 per unit of risk. If you would invest  8,968  in Boston Scientific Corp on December 29, 2024 and sell it today you would earn a total of  1,112  from holding Boston Scientific Corp or generate 12.4% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Boston Scientific Corp  vs.  Immunome

Boston Scientific Corp

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Boston Scientific Corp are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Boston Scientific showed solid returns over the last few months and may actually be approaching a breakup point.

Immunome

Risk-Adjusted Performance

Very Weak

Over the last 90 days Immunome has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Boston Scientific and Immunome

The main advantage of trading using opposite Boston Scientific and Immunome positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Boston Scientific position performs unexpectedly, Immunome can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunome will offset losses from the drop in Immunome's long position.

The idea behind Boston Scientific Corp and Immunome pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.